Extensive data on novel triglyceride-lowering agents were presented at the American Heart Association Scientific Sessions in New Orleans (7-10 November 2025), including from the Phase 3 CORE-TIMI 72a and CORE2-TIMI 72b studies of olezarsen in severe hypertriglyceridaemia, a first-in-human study of ANGPTL3 gene editing, and a Phase 2 study of a triple action TG-lowering agent. There were also new findings on the effects of pemafibrate on fibrinogen in patients with coronary artery disease.
Read the reports:
- CORE studies confirm benefits of olezarsen in sHTG
- First human ANGPTL3 gene editing study shows TG and cholesterol reduction
- Triple action TG-lowering agent reduces liver fat in severe hypertriglyceridaemia
- Pemafibrate demonstrates fibrinogen lowering in coronary artery disease
Reporting by Jenny Bryan
